---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-039878"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:38:48.808354+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands

## Summary
- Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).
- Raised $64M ($50M public offering + $14M ATM) in July 2025; cash+investments $117.5M at June 30; runway into H1 2028.
- Expanded Almirall collaboration: second target elected for dermatology; up to $650M in potential milestones across two programs.
- ABS-101 Phase 1 interim data expected H2 2025; ABS-201 on track for Phase 1/2a start early 2026 with efficacy readout H2 2026.

## SEC filing metadata
- accession: 0001628280-25-039878
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/0001628280-25-039878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/absc-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-039878
- JSON: https://secwatch.observer/filing/0001628280-25-039878.json
- Plain text: https://secwatch.observer/filing/0001628280-25-039878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.